Recro Pharma’s intravenous painkiller succeeds in trial, shares soar

From Reuters:

Recro Pharma Inc said an intravenous version of its lead painkiller was successful in the first of two pivotal late-stage trials, sending the company’s shares surging 50 percent in trading after the bell.

The drug, Meloxicam, was being evaluated to treat acute pain in patients after a bunionectomy surgery, which involves removing or realigning soft tissue and bones in the joint of the big toe.

Meloxicam is a non-opioid drug, a class of drugs that do not have the side effects associated with commonly prescribed opioid drugs. These effects include addiction, constipation and respiratory distress.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: